Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / U.S. markets rallied on Friday, despite trade uncertainties and weak employment data, as a surge in Apple led to strong gains by the tech sector. The Dow Jones Industrial Average gained 1.39 percent to close at 24,262.51, while the S&P 500 Index declined 1.28 percent to close at 2,663.42. The Nasdaq Composite Index fell 1.71 percent to close at 7,209.62.
"Apple is releasing a lot of energy in tech shares today. It's obviously a big bode of confidence to have an investor like Buffett take such a big position, and the company just reported strong results, so there's a lot of goodwill around the stock," said Art Hogan, chief market strategist at Wunderlich Securities.
RDI Initiates Coverage on:
Sarepta Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=SRPT
Alnylam Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ALNY
Sarepta Therapeutics' stock jumped 14.81% Friday, to close the day at $89.75. The stock recorded a trading volume of 5,609,389 shares, which was above its three months average volume of 1,366,937 shares. In the last year, Sarepta Therapeutics' shares have traded in a range of 28.82 - 90.99. The share price has gained 211.42% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $77.82 is above its 200-day moving average of $63.94. Shares of Sarepta Therapeutics have gained roughly 25.10 percent in the past month and are up 61.3 percent year-to-date.
Access RDI's Sarepta Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SRPT
On Friday, shares of Alnylam Pharmaceuticals recorded a trading volume of 2,645,346 shares, which was above the three months average volume of 1,039,3030 shares. The stock ended the day 4.57% higher at $92.35. The share price has fallen 40.03% from its 52-week high with a 52-week trading range of 52.03 - 153.99. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $107.33 is below its 200-day moving average of $122.09. Shares of Alnylam Pharmaceuticals have fallen roughly 2.87 percent in the past month and are down 27.31 percent year-to-date.
Access RDI's Alnylam Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ALNY
Our Actionable Research on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
